Company / Operating Cash Flow
Actinium Pharmaceuticals, Inc. Operating Cash Flow History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$24.6M
FY2025
5-year range
-$47.3M / $8.6M
FY2021-FY2025
Trend
+48.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 6 years, ranging from -$47M in FY2024 to $9M in FY2023.
Based on SEC 10-K filings.
-$25M in FY2025.
Declined from $9M to -$25M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 48.1% year-over-year.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$24.6M | +48.1% |
| FY2024 | -$47.3M | -647.6% |
| FY2023 | $8.6M | +141.4% |
| FY2022 | -$20.9M | +3.5% |
| FY2021 | -$21.6M | -4076.5% |
| FY2011 | -$517.6K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026